CASK
MOLECULAR TARGETcalcium/calmodulin dependent serine protein kinase
CASK (calcium/calmodulin dependent serine protein kinase) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CASK
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ruxolitinib | 4.23 | 68 |
| 2 | bosutinib | 4.08 | 58 |
| 3 | bms 387032 | 3.47 | 31 |
| 4 | tae 684 | 3.43 | 30 |
| 5 | fedratinib | 3.40 | 29 |
| 6 | at 7519 | 3.33 | 27 |
| 7 | lestaurtinib | 3.04 | 20 |
| 8 | pha 665752 | 2.71 | 14 |
| 9 | rg 547 | 2.08 | 7 |
| 10 | Crizotinib | 0.69 | 1 |
About CASK as a Drug Target
CASK (calcium/calmodulin dependent serine protein kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented CASK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CASK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.